BAVENCIO

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Japan, Lithuania, Netherlands, Poland, Romania, Singapore, Spain, Turkey, UK.

Active ingredients

The drug BAVENCIO contains one active pharmaceutical ingredient (API):

1	Avelumab UNII KXG2PJ551I - AVELUMAB
	Avelumab is a human immunoglobulin G1 (IgG1) monoclonal antibody directed against programmed death ligand 1 (PD-L1). Avelumab binds PD-L1 and blocks the interaction between PD-L1 and the programmed death 1 (PD-1) and B7.1 receptors. This removes the suppressive effects of PD-L1 on cytotoxic CD8+ T-cells, resulting in the restoration of anti-tumour T-cell responses.
	Read more about Avelumab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
BAVENCIO Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01FF04	Avelumab	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FF PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
Discover more medicines within L01FF04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	11671G, 11679Q, 11685B, 11695M
BR	Câmara de Regulação do Mercado de Medicamentos	525418100050401
CA	Health Products and Food Branch	02469723
EE	Ravimiamet	1753275
ES	Centro de información online de medicamentos de la AEMPS	1171214001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	480316
FR	Base de données publique des médicaments	60199966
GB	Medicines & Healthcare Products Regulatory Agency	348648
HK	Department of Health Drug Office	65956
IL	מִשְׂרַד הַבְּרִיאוּת	8147
JP	医薬品医療機器総合機構	4291438A1022
LT	Valstybinė vaistų kontrolės tarnyba	1083944
NL	Z-Index G-Standaard, PRK	148008
PL	Rejestru Produktów Leczniczych	100400386
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W65131001
SG	Health Sciences Authority	15672P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699808770134
US	FDA, National Drug Code	44087-3535